OptiBiotix Health plc

("OptiBiotix" or the "Company")

Issue of Options and Related Party Transaction

OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol, diabetes and skincare, announces that, the Company has issued 6,099,135 options over new ordinary shares with an exercise price of 16 pence per share ("New Options") to Stephen O'Hara, CEO of the Company. The New Options expire on 17 December 2034 and vest on the first anniversary of the options being granted being 17 December 2025.

The issue of the New Options follows the expiration of 6,099,135 options over new ordinary shares with an exercise price of 8 pence per share, granted to Stephen O'Hara, which expired in September 2024.

Related Party Transaction

The issuance of the New Options to Stephen O'Hara ("Transaction") is a related party transaction pursuant to Rule 13 of the AIM Rules.

The directors of the Company independent of the Transaction, having consulted with the Company's nominated adviser, Cairn Financial Advisers LLP, consider the terms of the Transaction to be fair and reasonable insofar as the Company's shareholders are concerned.

This announcement contains information which, prior to its disclosure, was considered inside information for the purposes of the UK Market Abuse Regulation and the Directors of the Company are responsible for the release of this announcement.

For further information, please contact:

About OptiBiotix - www.optibiotix.com

OptiBiotix Health plc (AIM: OPTI), which was formed in March 2012, brings science to the development of compounds which modify the human microbiome - the collective genome of the microbes in the body - in order to prevent and manage human disease and promote wellness.

OptiBiotix has an extensive R&D programme working with leading academics in the development of microbial strains, compounds, and formulations which are used as active ingredients and supplements. More than twenty international food and healthcare supplement companies have signed agreements with OptiBiotix to incorporate their human microbiome modulators into a wide range of food products and drinks.

OptiBiotix is also developing its own range of consumer supplements and health products. The Company's current areas of focus include obesity, cardiovascular health, and diabetes.